Blood sampling: At the diagnosis of meningioma recurrence: a blood sample of 28 mL of whole blood (i.e., 4 EDTA tubes of 7 mL each) and at the end of meningioma recurrence treatment: a blood sample of 28 mL of whole blood (i.e., 4 EDTA tubes of 7 mL each) will be collect.
Lumbar puncture: At the time of diagnosis of meningioma recurrence :a cerebrospinal fluid (CSF) sample obtained by lumbar puncture, in the absence of contraindications verified by the investigator, collected in one dry tube of 4 mL.
Study summary
The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Over 18 years of age
* Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024
* Tumour expressing SSTR2A on the initial surgical specimen
* Clinical and/or radiological recurrence as determined by MRI imaging (progression of a residual lesion OR appearance of a new lesion consistent with a meningioma at the surgical site or elsewhere)
Exclusion Criteria:
* Other active ongoing cancer
* Contraindications to lumbar puncture:
* Intracranial hypertension with meningioma exerting a mass effect and obstruction of the cerebrospinal fluid (CSF) pathway/risk of trans-tentorial or amygdalar herniation
* Blood clotting disorder with risk of haematoma at the puncture site (anticoagulant treatment at therapeutic dose or antiplatelet therapy, thrombocytopenia or thrombopathy)
* Infection at the puncture site
* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)
* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)
* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)
* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)
* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)
* Failure to obtain written informed consent
Primary outcome measure(s)
Detection rate of circulating tumour cells (CTC) in blood — Before treatment of meningioma recurrence and at the end of meningioma recurrence treatment on Day 90 (± 15 days) in case of radiotherapy, or on Day 1 post-surgery in case of surgery i.e the proportion of patients with at least one CTC in the venous blood sample
Detection rate of circulating tumour cells (CTC) in cerebrospinal fluid — Before treatment of meningioma recurrence i.e the proportion of patients with at least one CTC in the cerebrospinal fluid
Trial sites (1)
Facility
City
Region
Status
CHU de Montpellier
Montpellier
France
Recruiting
More University Hospital, Montpellier trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
